WILLIAM J. LINK PHD - 15 Dec 2025 Form 4 Insider Report for Tarsus Pharmaceuticals, Inc. (TARS)

Role
Director
Signature
/s/ Scott Sieckert, Attorney-in-Fact
Issuer symbol
TARS
Transactions as of
15 Dec 2025
Net transactions value
-$1,864,678
Form type
4
Filing time
17 Dec 2025, 16:07:49 UTC
Previous filing
18 Sep 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
LINK WILLIAM J PHD Director C/O TARSUS PHARMACEUTICALS, INC., 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE /s/ Scott Sieckert, Attorney-in-Fact 17 Dec 2025 0001228684

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TARS Common Stock Sale $407,717 -5,046 -3.6% $80.80 136,286 15 Dec 2025 Direct F1, F2
transaction TARS Common Stock Sale $515,516 -6,306 -4.6% $81.75 129,980 15 Dec 2025 Direct F1, F3
transaction TARS Common Stock Sale $94,584 -1,148 -0.88% $82.39 128,832 15 Dec 2025 Direct F1, F4
transaction TARS Common Stock Sale $458,433 -5,680 -54% $80.71 4,766 15 Dec 2025 By Link Family Enterprise, LP F5, F6, F7
transaction TARS Common Stock Sale $388,429 -4,766 -100% $81.50 0 15 Dec 2025 By Link Family Enterprise, LP F5, F7, F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 8, 2025.
F2 The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $80.21 to $81.20. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $81.21 to $82.19. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $82.23 to $82.92. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 The sales were not effected by a sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F6 The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $80.21 to $81.20. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F7 The Reporting Person may be deemed to beneficially own the shares indirectly by reason of the Reporting Person as the controlling member of Link Family Enterprise, LP.
F8 The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $81.21 to $81.79. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.